MET and neoplasm: Patients whose tumours had both T790M mutations and MET copy-number gain before rociletinib treatment (n=16) displayed significantly less tumour shrinkage than patients whose tumours were T790M-mutant but lacked MET amplification by FISH (n=33; Fig. 5c, average change in target lesions using RECIST methodology of −13.8 versus −36.5%; P<0.05, Wilcoxon rank-sum test).